31 reports

  • diabetes and obesity are significant secondary causes of dyslipidemia. In addition to
  • 4.1 DISEASE BACKGROUND

A genetic basis for coronary artery disease.

  • Cholesterol
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company
  • Risk Factors and Comorbidities for Dyslipidemia
  • 2.2 RISK FACTORS AND COMORBIDITIES

Plos One; ##(##): ##-##.

  • Cholesterol
  • China
  • Germany
  • United States
  • Forecast

Dyslipidemia Drugs Market: - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023 Chapter ## Introduction ##. ## Report Description ##. ## Market Segmentation ##. ## Research Methodology ##. ##. ## Sources ##. ##. ##. ## Secondary Research ##. ##. ##. ## Primary Research ##. ##. ##. ## Assumption ##. ##

  • Cholesterol
  • Therapy
  • United States
  • Company Financials
  • Market Size
  • 3.1.1 ETIOLOGY
  • 2.1 CATALYST

A genetic basis for coronary artery disease.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

Drivers and their Impact Impact on Key Customer Category Increase in Incidence of High Cholesterol Increase in Prevalence of Chronic Diseases Changes in Cholesterol Treatment Guidelines Increase in Aging Population Expected Entry of Cost- Effective OTC Versions ## ## ## ## ## Hospitals Low Low

  • Cholesterol
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • R&D Progress Research and Development Brief
  • Licensed From Company

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Cardiology
  • Cardiovascular Disease
  • Cholesterol
  • Therapy
  • Pfizer Inc.
  • 3.1.1 ETIOLOGY
  • 2.1 CATALYST

A genetic basis for coronary artery disease.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 3.1.1 ETIOLOGY
  • 2.1 CATALYST

A genetic basis for coronary artery disease.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 3.1.1 ETIOLOGY
  • 2.1 CATALYST

A genetic basis for coronary artery disease.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 2.1 CATALYST

A genetic basis for coronary artery disease.

  • Cholesterol
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.

The EFSA Journal 2008a, ##:##-##.

  • Cholesterol
  • World
  • Danone SA
  • Raisio Group
  • Unilever PLC
  • R&D Progress Research and Development Brief
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Product Development Milestones

THE MOLECULES DEVELOPED BY COMPANIES IN PHASE III, PHASE II, PHASE I, PRECLINICAL AND DISCOVERY STAGES ARE ##, ##, ##, ## AND ## RESPECTIVELY.

  • Cardiovascular Disease
  • Cholesterol
  • Hospital
  • Therapy
  • Pfizer Inc.
  • DEC 19, 2016: CAPSTONE THERAPEUTICS ANNOUNCES PROFOUND, RAPID LDL CHOLESTEROL REDUCTION IN AEM-28-14 PRIMATE STUDY
  • 02/21/2017: UAB DEVELOPING NEW PEPTIDE TO COMBAT A DISORDER THAT CAUSES HEART ATTACKS AT EARLY AGE

FH is a genetic condition that results from the body' s inability to clear low-density lipoprotein (LDL), or bad cholesterol, from the blood.

  • Cholesterol
  • Therapy
  • United States
  • Deals & Alliance
  • LipimetiX Development LLC
  • Clinical Trial profile. 11 Trial Title
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World

Core operating income was USD ##. ## billion (-##%, +##% cc).

  • Cholesterol
  • Clinical Trial
  • Diagnostics
  • United States
  • GlobalData's company
  • Clinical Trial profile. 28 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Apolipoprotein A I (APOA1) - Featured News & Press Releases

The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Cholesterol
  • Therapy
  • World
  • Product Initiative
  • Cerenis
  • Nov 07, 2017: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results

Development Program and Company Highlights August 2017: December 2017: Planned publication of results from Mendelian randomization studies that genetically validate ACL inhibition, the enzyme target of bempedoic acid.

  • Cholesterol
  • Therapy
  • United States
  • Corporate Finance
  • Esperion Therapeutics, Inc.
  • R&D Progress Research and Development Brief
  • R&D Progress Research and Development Brief

ApoE polymorphic alleles are the main genetic determinants of Alzheimer disease.

  • Cholesterol
  • Therapy
  • United States
  • Product Initiative
  • LipimetiX Development LLC
  • CER-001 - DRUG PROFILE
  • APOLIPOPROTEIN A-I (APOA-I) - FEATURED NEWS & PRESS RELEASES

The molecules developed by Companies in Phase III, Phase II and Preclinical stages are ##, ## and ## respectively.

  • Cholesterol
  • Therapy
  • World
  • Product Initiative
  • Cerenis
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • EVINACUMAB - DRUG PROFILE

The study patients diagnosis is confirmed both genetically and phenotypically.

  • Cardiovascular Disease
  • Cholesterol
  • Chronic Disease
  • Pharmaceutical
  • Amarin Corporation plc
  • Effect of Multiple Doses of Fenofibrate on the Multiple-Dose Pharmacokinetics of Pravastatin in Healthy Subjects
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cholesterol
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

## ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## ## Medpace Holdings Inc ## ## ## ## ## ## ## AbbVie Inc ## ## ## ## ## ## ## Ionis Pharmaceuticals Inc ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## Solen

  • Cholesterol
  • Clinical Trial
  • Therapy
  • World
  • AstraZeneca PLC

All three FCS patients had a genetic confirmation of FCS, no detectable LPL activity and baseline triglyceride levels greater than ##, ## mg/ dL.

  • Cholesterol
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Research and Development Brief
  • DYSLIPIDEMIA - PIPELINE BY ALNYLAM PHARMACEUTICALS INC, H2 2017

The abstract is entitled as Genetic Target Validation for ATP-Citrate Lyase Inhibition".

  • Cholesterol
  • Chronic Disease
  • United States
  • World
  • Product Initiative
  • R&D Progress Research and Development Brief

ApoE polymorphic alleles are the main genetic determinants of Alzheimer disease.

  • Cholesterol
  • Therapy
  • United States
  • Product Initiative
  • LipimetiX Development LLC
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • Mixed Dyslipidemia - Product Development Milestones

FH is an inherited condition caused by genetic mutations which lead to high levels of LDL-C at an early age, and it is estimated that less than one per cent of people with FH (heterozygous and homozygous forms) in Canada are diagnosed. ## HeFH prevalence in Canada is highest in Que

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Amgen Inc.
  • LOMITAPIDE MOVED FROM FILED TO MARKETED FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN THE UNITED STATES.

FCS is a rare genetic disorder that affects approximately one to two out of a million people.

  • Cholesterol
  • United States
  • Company Operations
  • Product Initiative
  • Aegerion Pharmaceuticals, Inc.

The prominent features of this report are - ##.

  • Cholesterol
  • Clinical Trial
  • Pharmaceutical
  • Therapy
  • World

All three FCS patients had a genetic confirmation of FCS, no detectable LPL activity and baseline triglyceride levels greater than ##, ## mg/ dL.

  • Cholesterol
  • Pharmaceutical
  • United States
  • Product Initiative
  • Acasti Pharma Inc.